Abstract
Monocytes infiltrating tumors acquire various states that distinctly impact cancer treatment. Here, we show that resistance of tumors to radiotherapy (RT) is controlled by the accumulation of monocyte-derived dendritic cells (moDCs). These moDCs are characterized by the expression of CD301b and have a superior capacity to generate regulatory T cells (Tregs). Accordingly, moDC depletion limits Treg generation and improves the therapeutic outcome of RT. Mechanistically, we demonstrate that granulocyte–macrophage colony-stimulating factor (GM-CSF) derived from radioresistant tumor cells following RT is necessary for the accumulation of moDCs. Our results unravel the immunosuppressive function of moDCs and identify GM-CSF as an immunotherapeutic target during RT.
Funding Information
  • National Institute of Health (R01CA219994, S10OD016318-01, S10OD018208-01)
  • Life Sciences Research Foundation
  • Stanford Medicine
  • Canadian Institute of Health Research
  • National Science Foundation Graduate Research Fellowship Program (2019276237)
  • Stanford University

This publication has 94 references indexed in Scilit: